Zynteglo Is Cost Effective At $2.1M, ICER Proposes; Validation For Bluebird’s Pivot To US?

 
• By Cathy Kelly
ICER Analysis Is Based On A Price Estimate For Zynteglo In US • Source: Alamy

More from Health Technology Assessment

More from Market Access